Alkem Laboratories Limited (ALKEM) — Corporate Action

📢 Key Event
Shareholders to vote on Alkem's amalgamation scheme with Adroit Biomed on August 17, 2026

🔄 What Changed
Three-fourths majority in value required for scheme approval; remote e-voting enabled

🔮 What's Next
NCLT and SEBI approvals required post-meeting

💡 Investor Takeaway
Shareholders must vote remotely to approve the merger, which consolidates ownership with no immediate financial change for them

Alkem Laboratories announced a shareholders' meeting on August 17, 2026, to approve a scheme of amalgamation with Adroit Biomed Limited, its wholly owned subsidiary, under NCLT supervision. Shareholders will vote remotely via e-voting from August 12-16, 2026, requiring a three-fourths majority in value. The meeting will be held virtually, with no proxy facility, and resolutions will empower the board to modify terms or waive conditions. The scheme involves no cash or share consideration, and regulatory approvals from NCLT and SEBI are pending. Documents including the scheme and financial statements are available for inspection.

📄 View Original Announcement (PDF)

📊 Stock Analysis — ALKEM ✨ Ask AI About This